Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 filgotinib in active axial spondyloarthritis
NL-OMON60499Phase 3Completed
- Sponsor
- Alfasigma
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in axial spondyloarthritis (axSpA) comparing Filgotinib 200 mg with Placebo (2 arms). Primary endpoint: ASAS40 response at week 16. Started Aug 2023; status: completed.
02
Drugs
filgotinib
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on NL-OMON60499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60499.